MEDIPOST signs a joint research agreement with LG Chemical

MEDIPOST Clears Product Approval Renewal of CARTISTEM by the Ministry of Food and Drug Safety(MFDS)

MEDIPOST, hits a record high in 1Q sales…Operating profits turn around

MEDIPOST, announces a domestic and international clinical experience at the ISCT annual meeting

MEDIPOST, announces the clinical trial achievements at Bio USA

MEDIPOST’s Injectable Cell Therapeutic for Knee Osteoarthritis Receives Phase 1 Clinical Trial Approval

MEDIPOST Treats First Patient with Injectable Cell Therapeutic for Knee Osteoarthritis

MEDIPOST to Expand the GMP facility to increase manufacturing capacity for CARTISTEM and new pipeline of products

MEDIPOST Receives Approval for Phase III Clinical Trial of CARTISTEM for the Treatment of Osteochondral Cartilage Defects in Ankle Joint

MEDIPOST Clears Phase II Clinical Trial Approval for CARTISTEM in Japan

MEDIPOST receives approval for processing the phase 3 clinical trial of CARTISTEM in Japan

MEDIPOST speeds up its global commercialization of CARTISTEM by requesting official product approval in Malaysia